DARE
NASDAQDare Bioscience Inc.
News · 26 weeks67-36%
2026-04-192026-10-11
Mix3190d
- SEC Filings15(48%)
- Other12(39%)
- Earnings2(6%)
- Offering1(3%)
- Market1(3%)
Latest news
25 items- PRDaré Bioscience Launches “CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and OpportunitiesNew video series featuring Founder, President and CEO Sabrina Martucci Johnson will provide investors with insights into Daré Bioscience’s growing commercial portfolio, clinical pipeline and strategic priorities Access the CEO Corner here SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the launch of its CEO Corner, a new video series featuring Founder, President and CEO Sabrina Martucci Johnson. Through CEO Corner, Ms. Johnson will provide investors with her perspective on Daré Bioscience’s busin
- PRDaré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific MeetingSAN DIEGO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that clinical data from a Phase 1 study that evaluated the Company’s proprietary Sildenafil Cream, 3.6% investigational product (Sildenafil Cream) will be presented at the Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA), taking place October 8-11, 2026, in Orlando, Florida. Annie Thurman, MD, FACOG, Medical Director of Daré Bioscience, will present "An Open-Label, Single-Dose, Randomized, Parallel-Cohort Study of
- SECSEC Form DEF 14A filed by Dare Bioscience Inc.DEF 14A - Dare Bioscience, Inc. (0001401914) (Filer)
- SECDare Bioscience Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- SECDare Bioscience Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV InfectionNew U.S. patent expands intellectual property foundation for DARE-HPV, a potential first-in-category treatment targeting persistent high-risk HPV infection DARE-HPV Phase 2 study underway with topline results expected in 2027; program supported by approximately $10 million in non-dilutive ARPA-H funding and a $2.0 million NIAID award DARE-HPV is designed to address a major treatment gap for the millions of U.S. women who experience high-risk HPV infection each year, for which there is currently no FDA-approved pharmacologic treatment SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the ga
- SECSEC Form PRE 14A filed by Dare Bioscience Inc.PRE 14A - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDaré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral SildenafilPublished Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience’s proprietary topical Sildenafil Cream, 3.6% At the 71 mg topical dose, mean maximum plasma concentration of sildenafil was approximately 187-fold lower than following a 50 mg oral dose Publication expands peer-reviewed clinical evidence supporting Daré Bioscience’s proprietary topical Sildenafil Cream formulation SAN DIEGO, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the publication of results from a Pha
- SECDare Bioscience Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDaré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-DemandView the video webcast here SAN DIEGO, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that its pre-recorded presentation for the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here. The presentation, featuring Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience, provides an overview of the Company as well as recent corporate and clinical developments. The on-demand presentation is available for viewing beginning today, Septemb
- SECDare Bioscience Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- SECSEC Form 424B3 filed by Dare Bioscience Inc.424B3 - Dare Bioscience, Inc. (0001401914) (Filer)
- SECSEC Form EFFECT filed by Dare Bioscience Inc.EFFECT - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDaré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm BirthNew NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million DARE-PTB2 is an early-stage, investigational program focused on developing a potential new therapeutic approach for the prevention of preterm birth SAN DIEGO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it received a new notice of award from the Eunice Kennedy Shriver National Institute of Child Health and Human Developmen
- PRDaré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand SeriesVideo webcast now available here SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it participated in the Virtual Investor "Why Now" on-demand series. For the webcast, Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience, presented the Company's investment thesis, highlighting its mission to advance innovative solutions that address significant unmet needs in women's health through a differentiated, science based and capital-efficient business model. Ms. Johnson un
- NEWSJTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOsNine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now?On-demand video series gives investors rapid access to company leadership, recent milestones, upcoming catalysts and the opportunities management believes investors should be watching todayAccess on demand conference here FRENCHTOWN, NJ / ACCESS Newswire / August 27, 2026 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced the release of its Virtual Investor "Why Now" On-Demand Conference, featuring a fast-paced series of 60-second presentations from the CEOs of nine publicly traded companies.The premise is simple: Why sho
- SECSEC Form S-1 filed by Dare Bioscience Inc.S-1 - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDaré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect SegmentPresident & CEO, Sabrina Martucci Johnson, discusses the Company’s shift to commercial stage, upcoming revenue opportunities, Ovaprene’s positive interim Phase 3 results and what could drive value over the next 12–18 monthsAccess the segment here SAN DIEGO, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience, participated in a Virtual Investor CEO Connect segment. As part of the segment, Ms. Johnson discussed the Company’s tr
- SECSEC Form D filed by Dare Bioscience Inc.D - Dare Bioscience, Inc. (0001401914) (Filer)
- SECSEC Form 253G2 filed by Dare Bioscience Inc.253G2 - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” ListSAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that its President and Chief Executive Officer, Sabrina Martucci Johnson, has been named to the Forbes 2026 "50 Over 50: Innovation" list, recognizing women who are making significant professional impact later in their careers. The recognition places Ms. Johnson among a distinguished group of innovators and entrepreneurs recognized by Forbes and underscores what Daré Bioscience believes is an increasingly important story for patients, the healthcare i
- SECDare Bioscience Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- SECSEC Form 424B5 filed by Dare Bioscience Inc.424B5 - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDaré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesSAN DIEGO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that it has entered into a definitive securities purchase agreement with institutional investors for the purchase and sale of 4,379,581 shares of the Company’s common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof), at a price of $1.37 per share of common stock (or $1.3699 per pre-funded warrant) in a registered direct offering priced at-the-market under Nasdaq rules. Each pre-funded warrant will be exercisable upon is
- SECSEC Form 10-Q filed by Dare Bioscience Inc.10-Q - Dare Bioscience, Inc. (0001401914) (Filer)
DARE FAQ
7 questionsWhat does Dare Bioscience Inc. do?
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil...Where does DARE stock trade?
Dare Bioscience Inc. (DARE) is listed on NASDAQ.What sector and industry is DARE in?
Dare Bioscience Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Dare Bioscience Inc. go public?
Dare Bioscience Inc. (DARE) completed its IPO in 2014.What are analysts saying about DARE?
Dare Bioscience Inc. has had 1 recent analyst action on file. The most recent action was from Roth Capital: Buy with a $1100.00 price target on 2021-06-30. Recent price targets cluster around $1100.00.What companies are similar to DARE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare DARE side-by-side with any of them on Quantisnow.How can I track DARE on Quantisnow?
Quantisnow aggregates Dare Bioscience Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DARE to receive live email and push alerts on every new disclosure.